The Russian-developed vaccine dubbed "Sputnik V" has shown some success in its early clinical trials.
The vaccine was first announced by Russia's President Vladimir Putin, adding that his daughter had also taken the vaccine.
Although, the announcement of the vaccine was met with doubts by experts across the world, with the World Health Organisation urging the European nation to put the vaccine "through all the stages" to ensure that it is safe for use on a wider scale.
In a study conducted and published by Lancet, a reputable medical journal, it was noted by researchers that the vaccine had recorded success in the early trials.
It was stated that the vaccine developed antibodies and did not show any "serious adverse events."
The report from the study showed that in two small trials, with 38 healthy adults as the subjects between ages 18 and 60, a two-part immunisation process was conducted.
READ ALSO: Putin Announces COVID-19 Vaccine Developed By Russia
It also added that the volunteers were kept under watch for 42 days and within the first three weeks, they had developed antibodies.
The study concluded that the vaccine was “safe, well-tolerated, and does not cause serious adverse events in healthy adult volunteers.”
Nigeria received samples of the vaccine on Friday, as delivered by the Russian Ambassador to Nigeria to the Health Minister, Osagie Ehanire, in Abuja.
0 Comment(s)